Replies to post #311253 on Avid Bioservices Inc (CDMO)

[Protector]

hutschi, thanks. VERY interesting information because it positions the RISK of the side effects of all type of cancer treatments and shows clearly that even the most recent ones are not protected from them.

As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer-related survival, regardless of the oncologic prognosis.
...
A better understanding of these research-practice gaps may advance research initiatives on the development of mechanism-based diagnoses and treatments for the effective clinical management of cardiotoxicity.

CAR-T was mentioned EXPLICITLY. No RONIN want to stop PS-tareting, R&D and monetise IP while PPHM, according to Dr. Wolchok of Memorial Sloan Kettering, says PS-targeting solves the problems mentioned above when combined with CAR-T:

Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities

AND PPHM wrote in the past 10-K that they HAVE a NEW platform READY for commercialising after final testing that was ongoing to TARGET about ANYTHING in (assuming in Cytometric terms).

I don't think this is the time to allow some party that just invested in PPHM to stop our R&D in PS-targeting. So let's not give them a majority in the BoD to do that, just some seats to prove themselves while in the process we remove those currently there that we no longer want and replace them with BETTER NEW candidates and keep CEO King as the fill rouge.

[BioBS2012]

Alrighty. Some more shiny objects for SK and team to pursue in their endless quest to run this company into the ground.